DHA Omega-3 Levels and Your Genetics
DHA Omega-3 Genetics: FADS2, APOE, and Synthesis Loci | ExomeDNA
By the ExomeDNA Research Team | Last reviewed May 2026
Research base: Robust.
What is DHA and how is it measured in blood?
Docosahexaenoic acid (DHA) is a 22-carbon omega-3 fatty acid that is the predominant polyunsaturated fatty acid in the human brain, where it accounts for roughly 97% of brain omega-3 fatty acids and approximately 10–20% of total brain fatty acids. It is also concentrated in the retina and heart. Blood DHA levels, measured here using nuclear magnetic resonance (NMR) spectroscopy in the UK Biobank cohort, reflect the total circulating DHA pool—spanning triglycerides, phospholipids, and cholesteryl esters in lipoprotein particles.
NMR spectroscopy provides a standardized, high-throughput measurement platform that captures hundreds of metabolites simultaneously from a single blood sample. Its use in the UK Biobank generated one of the largest single-cohort metabolomic datasets in human genetics, enabling well-powered genetic studies of DHA and related metabolites. Genetics influences circulating DHA through both biosynthesis capacity (how efficiently the body makes DHA from dietary precursors) and lipoprotein metabolism (how efficiently DHA-containing particles are processed and cleared).
The genetics behind DHA omega-3 levels
The strongest genetic signals for UK Biobank DHA levels include variants near SORT1, APOE, PCSK9, LIPC, CELSR2, CPT1A, APOA1, CETP, LIPG, LDLR, ST3GAL4, and FADS2. This gene set spans both biosynthesis and lipoprotein transport, with FADS2 being the distinctive biosynthesis signal differentiating this analysis from primarily transport-focused DHA studies.
FADS2 encodes fatty acid desaturase 2, also known as delta-6 desaturase. It catalyzes the first enzymatic step in converting alpha-linolenic acid (ALA, 18:3n-3)—the plant-based omega-3 found in flaxseed, chia, and walnuts—into the longer-chain omega-3 fatty acids EPA and eventually DHA. This desaturation step is rate-limiting in the biosynthesis cascade. Common variants in FADS2 reduce enzyme activity, resulting in lower endogenous conversion of ALA to DHA. For individuals with reduced FADS2 activity variants, dietary sources of preformed DHA become relatively more important for maintaining circulating levels.
APOE encodes apolipoprotein E, with three major isoforms (ε2, ε3, ε4) that differ in their binding affinity for lipoprotein receptors. APOE mediates the uptake of remnant particles carrying dietary DHA from chylomicron remnants and VLDL remnants via hepatic receptors. The ε4 isoform is associated with altered lipoprotein metabolism and has been linked to modified DHA handling—including potentially lower brain DHA levels—compared to the more common ε3 isoform. This makes APOE one of the most clinically relevant genetic influences on DHA metabolism.
UK Biobank NMR metabolomics provides one of the largest single-cohort genetic studies of circulating DHA, identifying FADS2 desaturase variants and APOE isoforms as key determinants of blood omega-3 levels alongside lipoprotein transport genes (Davyson et al., 2023).
SORT1 (sortilin) regulates hepatic VLDL secretion and is among the strongest lipoprotein genetics signals. PCSK9 and LDLR control LDL receptor density and the clearance rate of DHA-containing lipoprotein particles. APOA1 is the major HDL structural protein, and LIPC and LIPG are lipases that hydrolyze phospholipids in circulating lipoproteins, modulating how DHA moves between lipoprotein classes. CETP facilitates lipid exchange between HDL and LDL/VLDL, affecting the distribution of DHA across lipoprotein fractions.
What the research says
Davyson et al. (2023) used UK Biobank NMR metabolomics data to investigate the genetic architecture of circulating metabolites including DHA, with a focus on their relationships to brain health. The study used Mendelian randomization to examine causal relationships between circulating fatty acids—including DHA—and neurological outcomes. The findings identified genetic associations between DHA levels and brain-relevant endpoints, consistent with DHA's fundamental role in neural membrane composition.
The appearance of FADS2 in this analysis—alongside the standard lipoprotein transport genes—reflects that the UK Biobank NMR platform captures a broader DHA pool and that in this large single-cohort study, endogenous biosynthesis variants contributed measurably to circulating levels. This contrasts with studies where transport genes dominate, suggesting that the relative contributions of biosynthesis and transport to circulating DHA may vary across study designs and populations.
Mendelian randomization analyses using genetic instruments for circulating DHA identify favorable associations with neurological outcomes, consistent with DHA's role as the primary structural omega-3 in neural tissue and the most abundant long-chain PUFA in the human brain (Davyson et al., 2023).
How omega-3 DHA affects you
DHA is incorporated into the phospholipid bilayer of cell membranes throughout the body, where it influences membrane fluidity and the function of membrane-embedded proteins. In the brain, high DHA content in synaptic membranes supports neurotransmitter receptor function, ion channel activity, and the synthesis of neuroprotectin D1 and other specialized pro-resolving lipid mediators. Brain DHA accumulates throughout development and is maintained in adulthood through dietary intake and receptor-mediated uptake from lipoproteins.
The APOE connection is particularly relevant for brain DHA biology. Apolipoprotein E is the primary lipoprotein in the central nervous system, transporting lipids including DHA between glial cells and neurons. The ε4 isoform is associated with altered neuronal lipid handling, including modified DHA distribution to neural membranes. This makes APOE one of the most functionally significant genetic influences on brain-relevant DHA metabolism, independently of its well-characterized effects on systemic lipoprotein metabolism.
Working with your omega-3 DHA profile
FADS2 variants that reduce desaturation efficiency create a bottleneck at the first step of ALA→DHA conversion. For individuals with these variants, consuming plant-based ALA provides limited benefit for raising circulating DHA, because the conversion step itself is impaired. Preformed DHA from fatty fish (salmon, sardines, mackerel), fish oil, or algal oil supplements bypasses this bottleneck and directly increases circulating DHA regardless of FADS2 genotype.
For individuals with APOE ε4 variants, maintaining adequate DHA intake through regular dietary sources may be particularly relevant given the modified lipoprotein handling associated with this isoform. The overall evidence supports that consistent intake of preformed DHA raises blood and tissue DHA levels across genetic backgrounds, and that the omega-3 index (DHA plus EPA in red blood cells) provides a practical long-term measure of DHA status.
This content is provided for educational purposes only.
Related traits and genes
DHA genetics from UK Biobank overlaps with EPA, total omega-3 fatty acids, and HDL cholesterol. FADS2 is particularly associated with the full spectrum of long-chain omega-3 and omega-6 fatty acids—its variants affect desaturation capacity across the PUFA synthesis pathway. APOE appears across multiple lipoprotein traits and is one of the most pleiotropic genes in human genetics, influencing Alzheimer's risk, cardiovascular traits, and now DHA metabolism. SORT1 and PCSK9 are recurring signals in circulating lipid GWAS. ST3GAL4, a sialyltransferase, may affect lipoprotein particle glycosylation and clearance in ways that influence DHA-carrying lipoprotein half-life.